JNCI Journal of the National Cancer Institute最新文献

筛选
英文 中文
A new age for advance care planning and serious illness conversations in oncology. 肿瘤学中预先护理计划和重病对话的新时代。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-23 DOI: 10.1093/jnci/djae285
Finly Zachariah
{"title":"A new age for advance care planning and serious illness conversations in oncology.","authors":"Finly Zachariah","doi":"10.1093/jnci/djae285","DOIUrl":"https://doi.org/10.1093/jnci/djae285","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. BRCA1/2 基因致病变异携带者在接受降低风险的输卵管切除术后发生高级别浆液性癌。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-23 DOI: 10.1093/jnci/djae300
Iris A S Stroot, Joost Bart, Harry Hollema, Marise M Wagner, Refika Yigit, Helena C van Doorn, Joanne A de Hullu, Katja N Gaarenstroom, Marc van Beurden, Luc R C W van Lonkhuijzen, Brigitte F M Slangen, Ronald P Zweemer, Encarna B Gómez Garcia, Margreet G E M Ausems, Fenne L Komdeur, Christi J van Asperen, Muriel A Adank, Marijke R Wevers, Maartje J Hooning, Marian J E Mourits, Geertruida H de Bock
{"title":"High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.","authors":"Iris A S Stroot, Joost Bart, Harry Hollema, Marise M Wagner, Refika Yigit, Helena C van Doorn, Joanne A de Hullu, Katja N Gaarenstroom, Marc van Beurden, Luc R C W van Lonkhuijzen, Brigitte F M Slangen, Ronald P Zweemer, Encarna B Gómez Garcia, Margreet G E M Ausems, Fenne L Komdeur, Christi J van Asperen, Muriel A Adank, Marijke R Wevers, Maartje J Hooning, Marian J E Mourits, Geertruida H de Bock","doi":"10.1093/jnci/djae300","DOIUrl":"https://doi.org/10.1093/jnci/djae300","url":null,"abstract":"<p><strong>Background: </strong>Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents high-grade serous carcinoma (HGSC) in BRCA1/2 germline pathogenic variant (GPV) carriers. Still, some women develop HGSC after RRSO without pathologic findings. This study assessed long-term incidence and risk factors for developing HGSC after RRSO without pathologic findings.</p><p><strong>Methods: </strong>BRCA1/2 GPV carriers were selected from Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) cohort. Follow-up data for HGSC after RRSO were obtained from the Dutch Nationwide Pathology Databank (PALGA) and confirmed by histopathological review. Cumulative incidence rates of HGSC were calculated using Kaplan-Meier analyses. Cox proportional hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with an increased risk of HGSC following RRSO without pathologic findings.</p><p><strong>Results: </strong>A total of 2519 women were included, with a median follow-up of 13.4 years (range: 0.0-27.6). The 20-years cumulative incidence rate of HGSC was 1.5% (95% CI: 0.0-2.1) for BRCA1 and 0.2% (95% CI: 0.0-1.4) for BRCA2 GPV carriers. All women who developed HGSC underwent RRSO after the recommended age. Incomplete embedding of the RRSO specimen (HR: 4.2, 95% CI: 1.4-12.6), higher age at RRSO (HR per year: 1.1, 95% CI: 1.0-1.1), and carrying a BRCA1 GPV (HR: 12.1, 95% CI: 1.6-91.2) were associated with increased risk of HGSC.</p><p><strong>Conclusions: </strong>In BRCA1/2 GPV carriers, long-term incidence of HGSC after RRSO without pathologic findings was low. Strict adherence to guidelines regarding timely RRSO followed by complete specimen embedding can further reduce the risk of HGSC in the years following RRSO.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Nailing down" risk and improving outcomes in early-stage breast cancer. "确定 "风险,改善早期乳腺癌的治疗效果。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-22 DOI: 10.1093/jnci/djae278
Stephanie L Graff, Stacey Tinianov, Kevin Kalinsky
{"title":"\"Nailing down\" risk and improving outcomes in early-stage breast cancer.","authors":"Stephanie L Graff, Stacey Tinianov, Kevin Kalinsky","doi":"10.1093/jnci/djae278","DOIUrl":"https://doi.org/10.1093/jnci/djae278","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in cancer mortality under age 50 in 15 upper-Middle and high-income countries. 15 个中上收入和高收入国家 50 岁以下癌症死亡率趋势。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-22 DOI: 10.1093/jnci/djae288
Claudia Santucci, Silvia Mignozzi, Gianfranco Alicandro, Margherita Pizzato, Matteo Malvezzi, Eva Negri, Prabhat Jha, Carlo La Vecchia
{"title":"Trends in cancer mortality under age 50 in 15 upper-Middle and high-income countries.","authors":"Claudia Santucci, Silvia Mignozzi, Gianfranco Alicandro, Margherita Pizzato, Matteo Malvezzi, Eva Negri, Prabhat Jha, Carlo La Vecchia","doi":"10.1093/jnci/djae288","DOIUrl":"https://doi.org/10.1093/jnci/djae288","url":null,"abstract":"<p><strong>Background: </strong>Rising cancer incidence, particularly for colorectal cancer, has been reported in young adults. This study examined whether this is related to an increase in mortality.</p><p><strong>Methods: </strong>We analysed World Health Organization (WHO) mortality data among young adults aged 25-49 in 15 most populous upper-middle and high-income countries from 1990 to 2021 with reliable data. Mid-year populations were retrieved from the United Nations for the American Countries and from the WHO for the other countries. We compared age-standardised mortality rates (ASMRs) in 2019-2021 to 2009-2011 and performed joinpoint regression analysis for all cancers and selected most common cancer sites: colorectum, pancreas, lung and breast.</p><p><strong>Results: </strong>In 2019-2021, the highest ASMRs (per 100,000) were in Romanian males (38.6) and Argentinian females (45.9), while the lowest ones in Japan (males: 16.3; females: 22.7). ASMRs for colorectal cancers increased in 2019-2021 compared to 2009-2011 in nine countries among men and in seven countries among women. The highest increases were in the UK (males: +26.1%; females: +33.7%), Canada (males: +25.3%), and Mexico (males: +33.5%; females: +29.7%). Long-term analysis over the last three decades showed declining trends in total cancer mortality in the majority of countries, in lung cancer mortality across all countries, and in breast cancer in all countries except in Latin America.</p><p><strong>Conclusions: </strong>While mortality from common cancers has generally decreased over the past three decades, mortality from colorectal cancer has increased in some countries. This highlights the need to control the obesity epidemic and implement targeted surveillance strategies in young populations.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Elastography-based Risk Score for Predicting Hepatocellular Carcinoma Risk. 基于肝脏弹性成像的肝细胞癌风险预测分数
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-22 DOI: 10.1093/jnci/djae304
Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song
{"title":"Liver Elastography-based Risk Score for Predicting Hepatocellular Carcinoma Risk.","authors":"Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song","doi":"10.1093/jnci/djae304","DOIUrl":"https://doi.org/10.1093/jnci/djae304","url":null,"abstract":"<p><strong>Background & aims: </strong>Liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) accurately assesses fibrosis. We aimed to develop a universal risk score for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis.</p><p><strong>Methods: </strong>We systematically selected predictors and developed the risk prediction model (HCC-LSM) in the HBV training cohort (n = 2,251, median follow-up of 3.2 years). The HCC-LSM model was validated in an independent HBV validation cohort (n = 1,191, median follow-up of 5.7 years) and a non-viral chronic liver disease (CLD) extrapolation cohort (n = 1,189, median follow-up of 3.3 years). A HCC risk score was then constructed based on a nomogram. An online risk evaluation tool (LEBER) was developed using ChatGPT4.0.</p><p><strong>Results: </strong>Eight routinely available predictors were identified, with LSM levels showing a significant dose-response relationship with HCC incidence (P < .001 by log-rank test). The HCC-LSM model exhibited excellent predictive performance in the HBV training cohort (C-index = 0.866) and the HBV validation cohort (C-index = 0.852), with good performance in the extrapolation CLD cohort (C-index = 0.769). The model demonstrated significantly superior discrimination compared to six previous models across the three cohorts. Cut-off values of 87.2 and 121.1 for the HCC-LSM score categorized participants into low-, medium-, and high-risk groups. An online public risk evaluation tool (LEBER; http://ccra.njmu.edu.cn/LEBER669.html) was developed to facilitate the use of HCC-LSM.</p><p><strong>Conclusion: </strong>The accessible, reliable risk score based on LSM accurately predicted HCC development in patients with chronic hepatitis, providing an effective risk assessment tool for HCC surveillance strategies.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State-level disparities in cervical cancer prevention and outcomes in the U.S.: a modeling study. 美国各州在宫颈癌预防和治疗结果方面的差异:一项模型研究。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-21 DOI: 10.1093/jnci/djae298
Fernando Alarid-Escudero, Valeria Gracia, Marina Wolf, Ran Zhao, Caleb W Easterly, Jane J Kim, Karen Canfell, Inge M C M de Kok, Ruanne V Barnabas, Shalini Kulasingam
{"title":"State-level disparities in cervical cancer prevention and outcomes in the U.S.: a modeling study.","authors":"Fernando Alarid-Escudero, Valeria Gracia, Marina Wolf, Ran Zhao, Caleb W Easterly, Jane J Kim, Karen Canfell, Inge M C M de Kok, Ruanne V Barnabas, Shalini Kulasingam","doi":"10.1093/jnci/djae298","DOIUrl":"https://doi.org/10.1093/jnci/djae298","url":null,"abstract":"<p><strong>Background: </strong>Despite HPV vaccines' availability for over a decade, coverage across the US varies. While some states have tried to increase HPV vaccination coverage, most model-based analyses focus on national impacts. We evaluated hypothetical changes in HPV vaccination coverage at the national and state levels for California, New York, and Texas using a mathematical model.</p><p><strong>Methods: </strong>We developed a new mathematical model of HPV transmission and cervical cancer, creating US and state-level models, incorporating country- and state-specific vaccination coverage and cervical cancer incidence and mortality. We quantified the national and state-level impact of increasing HPV vaccination coverage to 80% by 2025 or 2030 on cervical cancer outcomes and the time to elimination defined as < 4 per 100k women.</p><p><strong>Results: </strong>Increasing vaccination coverage to 80% in Texas over ten years could reduce cervical cancer incidence by 50.9% (95% credible interval [CrI]: 46.6-56.1%) by 2100, from 1.58 (CrI : 1.19-2.09) to 0.78 (CrI : 0.57-1.02) per 100,000 women. Similarly, New York could see a 27.3% (CrI : 23.9-31.5%) reduction, from 1.43 (CrI : 0.93-2.07) to 1.04 (Crl : 0.66-1.53) per 100,000 women, and California a 24.4% (CrI : 20.0-30.0%) reduction, from 1.01 (Crl : 0.66-1.44) to 0.76 (Crl : 0.50-1.09) per 100,000 women. Achieving 80% coverage in five years will provide slightly larger and sooner reductions. If the vaccination coverage levels in 2019 continue, cervical cancer elimination could occur nationally by 2051 (Crl : 2034-2064), but state timelines may vary by decades.</p><p><strong>Conclusion: </strong>Targeting an HPV vaccination coverage of 80% by 2030 will disproportionately benefit states with low coverage and higher cervical cancer incidence. Geographically focused analyses can better inform priorities.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. 肥胖症特异性改善肺癌预后和二甲双胍的免疫疗法疗效。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-19 DOI: 10.1093/jnci/djae295
Randall J Smith, Robert Zollo, Sukumar Kalvapudi, Yeshwanth Vedire, Akhil Goud Pachimatla, Cara Petrucci, Garrison Shaller, Deschana Washington, Vethanayagam Rr, Stephanie N Sass, Aravind Srinivasan, Eric Kannisto, Sawyer Bawek, Prantesh Jain, Spencer Rosario, Joseph Barbi, Sai Yendamuri
{"title":"Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.","authors":"Randall J Smith, Robert Zollo, Sukumar Kalvapudi, Yeshwanth Vedire, Akhil Goud Pachimatla, Cara Petrucci, Garrison Shaller, Deschana Washington, Vethanayagam Rr, Stephanie N Sass, Aravind Srinivasan, Eric Kannisto, Sawyer Bawek, Prantesh Jain, Spencer Rosario, Joseph Barbi, Sai Yendamuri","doi":"10.1093/jnci/djae295","DOIUrl":"10.1093/jnci/djae295","url":null,"abstract":"<p><strong>Background: </strong>Pre-clinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non-small cell lung cancer (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC.</p><p><strong>Methods: </strong>We retrospectively analyzed two clinical cohorts and employed complementary mouse models to test our hypothesis. One cohort included NSCLC patients with overweight BMI (≥25, n = 511) and non-overweight BMI (<25, n = 232) who underwent lobectomy, evaluating metformin's impact on clinical outcomes. Another cohort examined metformin's effect on progression-free survival (PFS) after immune checkpoint inhibitors (ICI) in overweight (n = 284) vs non-overweight (n = 184) NSCLC patients. Metformin's effects on tumor progression, antitumor immunity, and ICI response in obese and normal-weight mice were assessed with lung cancer models.</p><p><strong>Results: </strong>Metformin is associated with increased recurrence-free survival in overweight patients (HR = 0.47 [95%CI = 0.24-0.94], p = .035) after lobectomy. It also corrected accelerated tumor growth in diet-induced obese mouse models in a lymphocyte-specific manner while reversing several mechanisms of immune suppression potentiated by obesity. PD-1 blockade coupled with metformin was more effective at limiting tumor burden in obese mice and correlated with PFS only in overweight patients on immunotherapy (HR = 0.60, [95%CI = 0.39-0.93], p = .024).</p><p><strong>Conclusions: </strong>Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population as well. This work identifies obesity as a potential predictive biomarker of metformin's anticancer and immunotherapy-enhancing properties in lung cancer while shedding light on the underlying immunological phenomena.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and Meta-Analysis. 新辅助治疗和切除术后局部胰腺导管腺癌的预后因素:系统综述和 Meta 分析。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-19 DOI: 10.1093/jnci/djae294
Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
{"title":"Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and Meta-Analysis.","authors":"Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink","doi":"10.1093/jnci/djae294","DOIUrl":"https://doi.org/10.1093/jnci/djae294","url":null,"abstract":"<p><strong>Introduction: </strong>Prognostic markers for overall survival (OS) in resected pancreatic ductal adenocarcinoma (PDAC) are well-established but remain unclear following neoadjuvant therapy (NAT). This systematic review and meta-analysis aimed to determine factors associated with OS following NAT in resected PDAC.</p><p><strong>Methods: </strong>The PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were systematically searched from inception till May 2024. Studies that reported univariable and multivariable hazard ratios (HRs) were included if patients underwent NAT and resection for localized PDAC. Study quality assessment was performed using the Newcastle-Ottawa scale. Meta-analysis was performed using generic inverse-variance random-effects models.</p><p><strong>Results: </strong>Among 2,208 unique articles identified by the search, 92 were included in the meta-analysis. Eighty-five of these were of 'good' and 7 of 'poor' quality. The NAT regimen was described in 84 studies, of which 62 included patients treated with FOLFIRINOX (FFX). Margin status, nodal disease, AJCC T-stage, and normalization of CA19-9 after NAT were prognostic for OS, while age, sex, perineural invasion, baseline tumor size, and baseline CA19-9 were not. The test for subgroup differences between ypN-substages was not significant in the multivariable model. Neoadjuvant FFX was associated with better survival than other regimens.</p><p><strong>Conclusions: </strong>This meta-analysis identified margin status, nodal disease, AJCC T-stage, and normalization of CA19-9 after NAT as prognostic factors for OS in patients with resected localized PDAC following NAT.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: A population-based study of COVID-19 mortality risk in US cancer patients. RE:基于人群的美国癌症患者 COVID-19 死亡风险研究。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-14 DOI: 10.1093/jnci/djae289
Jason Semprini, Nosayaba Osazuwa-Peters
{"title":"RE: A population-based study of COVID-19 mortality risk in US cancer patients.","authors":"Jason Semprini, Nosayaba Osazuwa-Peters","doi":"10.1093/jnci/djae289","DOIUrl":"https://doi.org/10.1093/jnci/djae289","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to simprini and Osazuwa-Peters. 回应 simprini 和 Osazuwa-Peters。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-14 DOI: 10.1093/jnci/djae290
Kyle A Mani, Xue Wu, Daniel E Spratt, Ming Wang, Nicholas G Zaorsky
{"title":"Response to simprini and Osazuwa-Peters.","authors":"Kyle A Mani, Xue Wu, Daniel E Spratt, Ming Wang, Nicholas G Zaorsky","doi":"10.1093/jnci/djae290","DOIUrl":"https://doi.org/10.1093/jnci/djae290","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信